Pfizer seeks FDA clearance for COVID-19 vaccine in younger children
(Reuters) - Pfizer Inc and BioNTech SE on Tuesday asked U.S. health regulators to authorize their COVID-19 vaccine in kids aged 5 to 11.
The application to the U.S. Food and Drug Administration comes as COVID-19 infections have soared in children, hitting their highest point in early September, according to data from the American Academy of Pediatrics.
(Reporting by Manas Mishra in Bengaluru; Editing by Saumyadeb Chakrabarty)
© Copyright Reuters Ltd. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Reuters Ltd.